Company profile
BNB Plus Corp.
NASDAQ: BNBX · Healthcare · Biotechnology
#786 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
33DFH 23DQ 57GM 21SS 24
v0.1 · 65/100 weight · provisional
↑ disclosure history, balance-sheet leverage · ↓ listing tenure, return on equity
Methodology →Revenue TTM
$2.1M
Rev growth YoY (TTM)
-39.6%
Net income (FY)
-$15.2M
Employees
26
as of 2026-08-27
Market cap
$210.5k
as of 2026-08-27
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.1M$2.1M2025
Net income-$15.2M-$15.2M2025
Operating income-$16.0M-$16.0M2025
Total assets$4.4M$4.4M2025
Liabilities$2.5M$2.5M2025
Equity$2.3M$2.3M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is BNB Plus Corp.’s revenue?
BNB Plus Corp. booked $2.1M in FY2025 revenue, contracting 38% year over year — slower than 78% of Healthcare companies we track, at a -709.5% net margin.
Peers · Healthcare
Aligos Therapeutics, Inc.47DAmerican Mobile Dental Corp.——Endexx Corporation——GeneLink, Inc.——Aeolus Pharmaceuticals, Inc.——Cyclerion Therapeutics, Inc.40DNeighbors
Suffolk →Key facts
CEOClay D. Shorrock
SectorHealthcare
IndustryBiotechnology
HeadquartersStony Brook, NY
ExchangeNASDAQ: BNBX
Employees26
IPO date2025-10-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.